StreetInsider.com News Articles

Form SCHEDULE 13G/A ANI PHARMACEUTICALS INC Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819932.html

Form SCHEDULE 13G/A ANI PHARMACEUTICALS INC Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260727/26819932.html

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

Fri, 24 Jul 2026 06:50:00 -0400

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here. Links to access the webcast and conference call will also be available

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

Fri, 24 Jul 2026 06:50:00 -0400

To view the webcast, please click here. Links to access the webcast and conference call will also be available

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

Fri, 24 Jul 2026 06:50:00 -0400

To view the webcast, please click here. Links to access the webcast and conference call will also be available

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

Fri, 24 Jul 2026 06:50:00 -0400

To view the webcast, please click here. Links to access the webcast and conference call will also be available

Form 4 ANI PHARMACEUTICALS INC For: Jul 18 Filed by: Cook Meredith

Tue, 21 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260721/26796087.html

Form 4 ANI PHARMACEUTICALS INC For: Jul 18 Filed by: Cook Meredith

Tue, 21 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260721/26796087.html

Form S-8 ANI PHARMACEUTICALS INC

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784636.html

Form S-8 ANI PHARMACEUTICALS INC

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784636.html

ANI Pharmaceuticals to appeal Delaware court rulings in CG Oncology case

Thu, 16 Jul 2026 16:36:58 -0400

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that a Delaware trial court denied its post-trial motions for a new trial and judgment as a matter of law in its case against CG Oncology, according to a press release dated July 16, 2026.

Judge Sheldon K. Rennie issued the ruling on July 16, 2026. ANI stated it intends to appeal to the Delaware Supreme Court.

The dispute centers on assets ANI sold to CG Oncology under a 2010 agreement between the parties. ANI is seeking to recover the value of those assets, including what it claims is a 5% running royalty on future worldwide

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Thu, 16 Jul 2026 16:34:00 -0400

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment
ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI’s post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Thu, 16 Jul 2026 16:34:00 -0400

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment
ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Thu, 16 Jul 2026 16:34:00 -0400

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment
ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

Thu, 16 Jul 2026 16:34:00 -0400

Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment
ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010

Canaccord Starts ANI Pharmaceuticals (ANIP) at Hold

Thu, 16 Jul 2026 16:05:33 -0400

Canaccord analyst Gary Newman initiates coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with a Hold rating and a price target of $91.00.

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $80.82 yesterday.

Form 4 ANI PHARMACEUTICALS INC For: Jul 13 Filed by: Cook Meredith

Tue, 14 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260714/26768177.html

Form 4 ANI PHARMACEUTICALS INC For: Jul 13 Filed by: Cook Meredith

Tue, 14 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260714/26768177.html

ANI Pharmaceuticals eye implant trial meets both primary endpoints

Mon, 13 Jul 2026 06:50:33 -0400

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that its Phase 4 SYNCHRONICITY clinical trial of fluocinolone acetonide intravitreal implant, marketed as ILUVIEN, met both co-primary endpoints at six months in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).

The intent-to-treat population included 108 patients. Mean best corrected visual acuity improved by 3.6 letters from a baseline of 62.5 letters to 65.8 letters at six months (p=0.0077). Mean central subfield thickness decreased by 157.5 microns from a baseline of 505.7 microns to 348.8 microns at six months (p<0.0001).

In the safety population, 29% of patients experienced treatment-related adverse

ANI Pharmaceuticals eye implant trial meets both primary endpoints

Mon, 13 Jul 2026 06:50:33 -0400

In the safety population, 29% of patients experienced treatment-related adverse

ANI Pharmaceuticals eye implant trial meets both primary endpoints

Mon, 13 Jul 2026 06:50:33 -0400

In the safety population, 29% of patients experienced treatment-related adverse

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni

Mon, 13 Jul 2026 06:50:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists.
Full results to be presented at an upcoming medical meeting

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni

Mon, 13 Jul 2026 06:50:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists.
Full results to be presented at an upcoming medical meeting

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni

Mon, 13 Jul 2026 06:50:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists.
Full results to be presented at an upcoming medical meeting

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chroni

Mon, 13 Jul 2026 06:50:00 -0400

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months
The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mg
Study evaluated patients with chronic NIU-PS in the U.S. Most patients in the study were treated by retina specialists.
Full results to be presented at an upcoming medical meeting

PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the